Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy.
Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy.
复制标题
DOI：
10.1016/j.reth.2020.11.001
复制
发表时间：
2020-12
影响因子：
4.3
通讯作者：
Huang H
中科院分区：
文献类型：
--
作者：
Liang Z;Cui J;Chang AH;Yu J;Hu Y;Huang H
图1所示。A.化疗后复发时和CD20/CD22 CART输注前淋巴细胞表型。B. CART输注后体温。C. CART输注后血浆中CRS相关细胞因子的变化。D.输注后CART细胞的增殖动态。CART细胞被标记为cd3 - car þ (Biotin-SP-AffiniPure F (ab) 2 Fragment Goat Anti-Human IgG, Jackson immunoresearch, 109-066-006；anti-CD3-PE-CY7, Biolegend, 300,420)。E.输注后CART细胞cd8 +、cd4 +比值的变化。F.骨髓中母细胞负荷（流式细胞术检测），化疗和CART细胞治疗期间CART细胞的百分比。G. CD20/CD22 CART复发前后靶向抗原的比较。未见CD20、CD22、CD19抗原丢失或表达减少。
Fig. 1. A. The phenotype of lymphoblasts at the time of relapse after chemotherapy and before CD20/CD22 CART infusion. B. The body temperature after CART infusion. C. The CRS related cytokines in plasma after CART infusion. D. Dynamic of CART cells expansion after infusion. The CART cells were gated as CD3þCARþ (Biotin-SP-AffiniPure F (ab) 2 Fragment Goat Anti-Human IgG, Jackson immunoresearch, 109-066-006; anti-CD3-PE-CY7, Biolegend, 300,420). E. The changes of CD8þ and CD4þ ratio of CART cells after infusion. F. The blasts burden in bone marrow (detected by flow cytometry), and the percentage of CART cells during the chemotherapy and CART cell treatment. G. Comparison of targeted antigens before and post CD20/CD22 CART relapse. There was no antigen loss or diminished expression of CD20, CD22, CD19.
CD22靶向的CAR T细胞在B-ALL中诱导对CD19靶向的CAR免疫疗法具有抗性的B-ALL。
影响因子：
82.9
作者：
Fry TJ;Shah NN;Orentas RJ;Stetler-Stevenson M;Yuan CM;Ramakrishna S;Wolters P;Martin S;Delbrook C;Yates B;Shalabi H;Fountaine TJ;Shern JF;Majzner RG;Stroncek DF;Sabatino M;Feng Y;Dimitrov DS;Zhang L;Nguyen S;Qin H;Dropulic B;Lee DW;Mackall CL
通讯作者：
Mackall CL
影响因子：
4.8
作者：
Jin, Aiyun;Feng, Jingjing;Huang, He
通讯作者：
Huang, He
影响因子：
10.1
作者：
Zah E;Lin MY;Silva-Benedict A;Jensen MC;Chen YY
通讯作者：
Chen YY